Experienced in Basal Cell Skin Cancer

Dr. Glen J. Weiss

Oncology
665 Washington St Unit 1015, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Basal Cell Skin Cancer
665 Washington St Unit 1015, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Glen Weiss is an Oncologist in Boston, Massachusetts. Dr. Weiss is rated as an Experienced provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pancreatic Cancer, and Gastrostomy.

His clinical research consists of co-authoring 129 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Basal Cell Skin Cancer.

Specialties
Oncology
Licenses
Internal Medicine in AZ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO

Locations

665 Washington St Unit 1015, Boston, MA 02111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
A Phase II Study of M6620 (VX-970) in Selected Solid Tumors
Enrollment Status: Completed
Publish Date: July 07, 2023
Intervention Type: Drug
Study Drug: M6620
Study Phase: Phase 2
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
Enrollment Status: Terminated
Publish Date: May 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab
A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab
Enrollment Status: Terminated
Publish Date: October 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Enrollment Status: Terminated
Publish Date: July 02, 2018
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

129 Total Publications

Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods.
Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods.
Journal: European radiology
Published: March 17, 2025
Similar Doctors
Advanced in Basal Cell Skin Cancer
Dr. Ann W. Silk
Oncology
Advanced in Basal Cell Skin Cancer
Dr. Ann W. Silk
Oncology

Dana-Farber Cancer Institute, Center For Cutaneous Oncology

450 Brookline Avenue, 
Boston, MA 
 (2.7 miles away)
617-632-6571
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ann Silk is an Oncologist in Boston, Massachusetts. Dr. Silk is rated as a Distinguished provider by MediFind in the treatment of Basal Cell Skin Cancer. Her top areas of expertise are Merkel Cell Carcinoma, Melanoma, Eccrine Porocarcinoma, Neuroendocrine Tumor, and Tissue Biopsy.

David E. Fisher
Experienced in Basal Cell Skin Cancer
Dr. David E. Fisher
Oncology | Pediatric Hematology Oncology | Hematology
Experienced in Basal Cell Skin Cancer
Dr. David E. Fisher
Oncology | Pediatric Hematology Oncology | Hematology
44 Binney Street, Dana 630 Dfci, 
Boston, MA 
 (2.6 miles away)
617-632-4916
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Fisher is an Oncologist and a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Fisher is rated as an Advanced provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Melanoma, Clear Cell Sarcoma, Squamous Cell Skin Carcinoma, Metastatic Brain Tumor, and Bone Marrow Transplant. Dr. Fisher is currently accepting new patients.

Experienced in Basal Cell Skin Cancer
Dr. Lori Pai
Oncology
Experienced in Basal Cell Skin Cancer
Dr. Lori Pai
Oncology

Tufts Medical Center Cancer Center

860 Washington St Bldg 8, 
Boston, MA 
 (0.1 miles away)
617-263-8312
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lori Pai is an Oncologist in Boston, Massachusetts. Dr. Pai is rated as a Distinguished provider by MediFind in the treatment of Basal Cell Skin Cancer. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weiss's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile